Search

Displaying results 3621 - 3630 of 9886 in total
  1. Drug

    LM-609

    go.drugbank.com/drugs/DB05787
    Experimental

    LM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood vessels, as well as on certain tumors.

  2. Drug

    Ulotaront

    go.drugbank.com/drugs/DB15665
    Investigational

    Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5 … SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia.

  3. Drug

    Eniporide

    go.drugbank.com/drugs/DB20221
    Experimental

    Eniporide is a small molecule drug. The usage of the INN stem '-poride' in the name indicates that Eniporide is a Na+/H+ antiport inhibitor. Eniporide has a monoisotopic molecular weight of 320.09 Da.

  4. Drug

    Zoniporide

    go.drugbank.com/drugs/DB20312
    Experimental

    Zoniporide has a monoisotopic molecular weight of 320.14 Da. … Zoniporide is a small molecule drug. The usage of the INN stem '-poride' in the name indicates that Zoniporide is a Na+/H+ antiport inhibitor.

  5. Drug

    Margetuximab

    go.drugbank.com/drugs/DB14967
    ApprovedInvestigational

    Of the various subtypes of breast cancer, HER2-positive breast cancer is characterized by _ERBB2_ overexpression, a higher grade, a more aggressive phenotype, and a worse prognosis compared to HER2-negative … However, due to its modified Fc region, margetuximab binds with higher affinity to both CD16A variants and exhibits weaker binding to the inhibitory CD32B Fc receptor, resulting in more efficient antibody-dependent

  6. Drug

    Vericiguat

    go.drugbank.com/drugs/DB15456
    ApprovedInvestigational

    deficiencies in its production (primarily due to insufficient NO bioavailability) in the pathogenesis of various cardiovascular diseases. … [A227458,A227488] Cyclic GMP acts as a second messenger, activating a number of downstream signaling cascades that elicit a broad variety of effects, and these diverse cellular effects have implicated

  7. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    However, it was voluntarily withdrawn from the market in 2010 due to safety concerns, increased patient deaths and insufficient evidence of clinical benefit during confirmatory trials [L941]. … Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora

  8. Drug

    Anthrax vaccine

    go.drugbank.com/drugs/DB11003
    ApprovedInvestigational

    [L47526] It is considered one of the most likely agents to be used in a biological attack. … Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*.

  9. Drug

    Cocoa butter

    go.drugbank.com/drugs/DB11086
    Approved

    Dyslipidemia is characterized by elevated levels of plasma triglyceride and very-low-density lipoprotein (VLDL) cholesterol due to overproduction of large triglyceride-enriched VLDL cholesterol particles … Still, it is a common active ingredient for prevention of skin dryness in cosmetic and skincare products.

  10. Drug

    Procainamide

    go.drugbank.com/drugs/DB01035
    Approved

    A derivative of procaine with less CNS action.

    Categories: Antiarrhythmics, Class Ia, OCT2 Substrates with a Narrow Therapeutic Index